These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 29330579

  • 21. [Varied immuno-related adverse events induced by immune-check point inhibitors - Nivolumab-associated psoriasiform dermatitis related with increased serum level of interleukin-6].
    Okiyama N, Tanaka R.
    Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(2):95-101. PubMed ID: 28603207
    [Abstract] [Full Text] [Related]

  • 22. FDG-PET in the evaluation of response to nivolumab in recurrent non-small-cell lung cancer.
    Higuchi M, Owada Y, Inoue T, Watanabe Y, Yamaura T, Fukuhara M, Hasegawa T, Suzuki H.
    World J Surg Oncol; 2016 Sep 05; 14(1):238. PubMed ID: 27595749
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma.
    Alnabulsi R, Hussain A, DeAngelis D.
    Orbit; 2018 Oct 05; 37(5):381-384. PubMed ID: 29381409
    [Abstract] [Full Text] [Related]

  • 25. Pituitary-adrenal dysfunction caused by nivolumab for head and neck cancer.
    Hihara K, Sato H, Okamoto I, Katsube Y, Maruyama R, Tomioka R, Tanaka H, Tsukahara K.
    Auris Nasus Larynx; 2019 Dec 05; 46(6):896-901. PubMed ID: 31350019
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Granulomatous and lichenoid dermatitis after IgG4 anti-PD-1 monoclonal antibody therapy for advanced cancer.
    Diaz-Perez JA, Beveridge MG, Victor TA, Cibull TL.
    J Cutan Pathol; 2018 Jun 05; 45(6):434-438. PubMed ID: 29468713
    [Abstract] [Full Text] [Related]

  • 28. Development of Cancer Immunotherapy Targeting the PD-1 Pathway.
    Kamimura N, Wolf AM, Iwai Y.
    J Nippon Med Sch; 2019 Jun 05; 86(1):10-14. PubMed ID: 30918149
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series.
    Tomelleri A, Campochiaro C, De Luca G, Cavalli G, Dagna L.
    Eur J Intern Med; 2018 Nov 05; 57():e11-e12. PubMed ID: 30076088
    [No Abstract] [Full Text] [Related]

  • 31. ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial.
    Wrangle JM, Velcheti V, Patel MR, Garrett-Mayer E, Hill EG, Ravenel JG, Miller JS, Farhad M, Anderton K, Lindsey K, Taffaro-Neskey M, Sherman C, Suriano S, Swiderska-Syn M, Sion A, Harris J, Edwards AR, Rytlewski JA, Sanders CM, Yusko EC, Robinson MD, Krieg C, Redmond WL, Egan JO, Rhode PR, Jeng EK, Rock AD, Wong HC, Rubinstein MP.
    Lancet Oncol; 2018 May 05; 19(5):694-704. PubMed ID: 29628312
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Immune checkpoint inhibitors and endocrinological side effects].
    Jørgensen LB, Bastholt L, Yderstræde K.
    Ugeskr Laeger; 2017 Dec 04; 179(49):. PubMed ID: 29212592
    [Abstract] [Full Text] [Related]

  • 36. Striking enhancement at the site of radiation for nivolumab-induced Stevens-Johnson syndrome.
    Shah KM, Rancour EA, Al-Omari A, Rahnama-Moghadam S.
    Dermatol Online J; 2018 Jun 15; 24(6):. PubMed ID: 30142712
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Late-onset isolated adrenocorticotropic hormone deficiency caused by nivolumab: a case report.
    Takeno A, Yamamoto M, Morita M, Tanaka S, Kanazawa I, Yamauchi M, Kaneko S, Sugimoto T.
    BMC Endocr Disord; 2019 Feb 19; 19(1):25. PubMed ID: 30782163
    [Abstract] [Full Text] [Related]

  • 39. Anti-PD1/PDL1 induced psoriasis.
    Voudouri D, Nikolaou V, Laschos K, Charpidou A, Soupos N, Triantafyllopoulou I, Panoutsopoulou I, Aravantinos G, Syrigos K, Stratigos A.
    Curr Probl Cancer; 2017 Feb 19; 41(6):407-412. PubMed ID: 29096940
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.